The Pharmacologic Basis for Clinical Differences among GLP-1 Receptor Agonists and DPP-4 Inhibitors

References

• . Nathan DM, Buse JB, Davidson MB, . Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32(1):193–203
   PubMed Web of Science ®Google Scholar
• . Rodbard HW, Jellinger PS, Davidson JA, . American Association of Clinical Endocrinologists/American College of Endocrinology. AACE/ACE diabetes algorithm for glycemic control. http://www.aace.com/publications. Published 2009. Accessed June 9, 2010
   Google Scholar
• . Elrick H, Stimmler L, Hlad CJ, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab. 1964; 24(10):1076–1082
   PubMed Web of Science ®Google Scholar
• . Nauck MA. Unraveling the science of incretin biology. Am J Med. 2009; 122( 6 suppl):S3–S10
   PubMed Web of Science ®Google Scholar
• . Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study. Lancet. 2002; 359(9309):824–830
   PubMed Web of Science ®Google Scholar
• . Drucker DJ. The biology of incretin hormones. Cell Metab. 2006; 3(3): 153–165
   PubMed Web of Science ®Google Scholar
• . Naslund E, Bogefors J, Skogar S, . GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol. 1999; 277(3 pt 2):R910–R916
   Google Scholar
• . Fehmann HC, Habener JF. Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology. 1992; 130(1):159–166
   PubMed Web of Science ®Google Scholar
• . Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: A physiological incretin in man. Lancet 1987; 2(8571): 1300–1304
   PubMed Web of Science ®Google Scholar
• . Nauck MA, Heimesaat MM, Behle K, . Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002; 87(3):1239–1246
   PubMed Web of Science ®Google Scholar
• . Delgado-Aros S, Kim DY, Burton DD, . Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol. 2002; 282(3):G424–G431
   PubMed Web of Science ®Google Scholar
• . Gutzwiller JP, Göke B, Drewe J, . Glucagon-like peptide-1: A potent regulator of food intake in humans. Gut. 1999; 44(1):81–86
   PubMed Web of Science ®Google Scholar
• . Gutzwiller JP, Drewe J, Göke B, . Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol. 1999; 276(5 pt 2):R1541–R1544
   Web of Science ®Google Scholar
• . Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007; 132(6):2131–2157
   PubMed Web of Science ®Google Scholar
• . Pratley RE, Nauck M, Bailey T, . Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: A 26-week, randomised, parallel-group, open-label trial. Lancet. 2010; 375(9724):1447–1456
   PubMed Web of Science ®Google Scholar
• . Ahren B. Dipeptidyl peptidase-4 inhibitors: Clinical data and clinical implications. Diabetes Care. 2007; 30(6):1344–1350
   PubMed Web of Science ®Google Scholar
• . Holst JJ, Deacon CF. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia. 2005; 48(4):612–615
   PubMed Web of Science ®Google Scholar
• . Herman GA, Bergman A, Stevens C, . Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006; 91(11):4612–4619
   PubMed Web of Science ®Google Scholar
• . Bergenstal RM, Wysham C, MacConell L, . Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomised trial. Lancet. 2010; 376(9739):431–439
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: A randomized, cross-over study. Curr Med Res Opin. 2008; 24(10):2943–2952
   PubMed Web of Science ®Google Scholar
• . Nelson P, Poon T, Guan X, Schnabel C, Wintle M, Fineman M. The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. Diabetes Technol Ther. 2007; 9(4):317–326
   PubMed Web of Science ®Google Scholar
• . Moretto TJ, Milton DR, Ridge TD, . Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008; 30(8): 1448–1460
   PubMed Web of Science ®Google Scholar
• . Cuddihy RM, Russell-Jones D, Hanefeld M, . Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes. Paper presented at: American Diabetes Association 71st Scientific Sessions; June 24-28, 2011; San Diego, CA
   Google Scholar
• . Garber A, Henry R, Ratner R, ; LEAD-3 Mono. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009; 373(9662):473–481
   PubMed Web of Science ®Google Scholar
• . Garber A, Henry RR, Ratner R, Hale P, Chang CT, Bode B; LEAD-3 (Mono) Study Group. Liraglutide, a once-daily human glucagon-like peptide-1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab. 2011; 13(4):348–356
   PubMed Web of Science ®Google Scholar
• . Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE; Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006; 29(12):2632–2637
   PubMed Web of Science ®Google Scholar
• . Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H; Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006; 49(11):2564–2571
   PubMed Web of Science ®Google Scholar
• . Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP; Sitagliptin Study 014 Investigators. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin. 2007; 23(6):1329–1339
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab. 2008; 10(5): 376–386
   PubMed Web of Science ®Google Scholar
• . Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: A randomized controlled trial. Diabetes Obes Metab. 2011; 13(3):258–267
   PubMed Web of Science ®Google Scholar
• . Klonoff DC, Buse JB, Nielsen LL, . Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008; 24(1):275–286
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005; 28(5):1092–1100
   PubMed Web of Science ®Google Scholar
• . Barnett AH, Burger J, Johns D, . Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther. 2007; 29(11):2333–2348
   PubMed Web of Science ®Google Scholar
• . Kim D, MacConell L, Zhuang D, . Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007; 30(6):1487–1493
   PubMed Web of Science ®Google Scholar
• . Nauck M, Frid A, Hermansen K, . Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009; 32(1):84–90
   PubMed Web of Science ®Google Scholar
• . Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006; 29(12):2638–2643
   PubMed Web of Science ®Google Scholar
• . Raz I, Chen Y, Wu M, . Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin. 2008; 24(2):537–550
   PubMed Web of Science ®Google Scholar
• . Rigby SP, Handelsman Y, Lai YL, Abby SL, Tao B, Jones MR. Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy. Endocr Pract. 2010; 16(1):53–63
   PubMed Web of Science ®Google Scholar
• . Scott R, Loeys T, Davies MJ, Engel SS; Sitagliptin Study 801 Group. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2008; 10(10):959–969
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Hissa MN, Garber AJ, ; Saxagliptin 014 Study Group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diabetes Care. 2009; 32(9):1649–1655
   PubMed Web of Science ®Google Scholar
• . Taskinen MR, Rosenstock J, Tamminen I, . Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011; 13(1):65–74
   PubMed Web of Science ®Google Scholar
• . Forst T, Uhlig-Laske B, Ring A, . Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. Diabet Med. 2010; 27(12):1409–1419
   PubMed Web of Science ®Google Scholar
• . Buse JB, Rosenstock J, Sesti G, ; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009; 374(9683):39–47
   PubMed Web of Science ®Google Scholar
• . Buse JB, Sesti G, Schmidt WE, ; Liraglutide Effect Action in Diabetes-6 Study Group. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care. 2010; 33(6):1300–1303
   PubMed Web of Science ®Google Scholar
• . Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2010; 26(7):540–549
   PubMed Web of Science ®Google Scholar
• . Pratley R, Nauck M, Bailey T, . One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: A randomised, parallel-group, open-label trial. Int J Clin Pract. 2011; 65(4):397–407
   PubMed Web of Science ®Google Scholar
• . Kendall DM, Riddle MC, Rosenstock J, . Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005; 28(5):1083–1091
   PubMed Web of Science ®Google Scholar
• . Blonde L, Klein EJ, Han J, . Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006; 8(4):436–447
   PubMed Web of Science ®Google Scholar
• . Zinman B, Hoogwerf BJ, Garcia SD, . The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: A randomized trial. Ann Intern Med. 2007; 146(7):477–485
   PubMed Web of Science ®Google Scholar
• . Russell-Jones D, Vaag A, Schmitz O, . Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): A randomised controlled trial. Diabetologia. 2009; 52(10):2046–2055
   PubMed Web of Science ®Google Scholar
• . Zinman B, Gerich J, Buse JB, ; LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009; 32(7):1224–1230
   PubMed Web of Science ®Google Scholar
• . Scott R, Wu M, Sanchez M, Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract. 2007; 61(1):171–180
   PubMed Web of Science ®Google Scholar
• . Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P; Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007; 9(5):733–745
   PubMed Web of Science ®Google Scholar
• . Hollander P, Li J, Allen E, Chen R. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab. 2009; 94(12):4810–4819
   PubMed Web of Science ®Google Scholar
• . Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: A randomised controlled trial. Int J Clin Pract. 2009; 63(9):1395–1406
   PubMed Web of Science ®Google Scholar
• . Bunck MC, Diamant M, Eliasson B, . Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care. 2010; 33(8):1734–1737
   PubMed Web of Science ®Google Scholar
• . Tushuizen ME, Bunck MC, Pouwels PJ, van Waesberghe JH, Diamant M, Heine RJ. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int. 2006; 26(8):1015–1017
   PubMed Web of Science ®Google Scholar
• . McGill JB. Liraglutide: Effects beyond glycaemic control in diabetes treatment. Int J Clin Pract Suppl. 2010; 64(167):28–34
   Google Scholar
• . Jendle J, Nauck MA, Matthews DR, . Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab. 2009; 11(12): 1163–1172
   PubMed Web of Science ®Google Scholar
• . Cunha DA, Ladriere L, Ortis F, . Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB. Diabetes. 2009; 58(12):2851–2862
   PubMed Web of Science ®Google Scholar
• . Bunck MC, Diamant M, Corner A, . One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: A randomized, controlled trial. Diabetes Care. 2009; 32(5):762–768
   PubMed Web of Science ®Google Scholar
• . Marre M, Shaw J, Brändle M, ; LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009; 26(3):268–278
   PubMed Web of Science ®Google Scholar
• . Brazg R, Xu L, Dalla MC, Cobelli C, Thomas K, Stein PP. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab. 2007; 9(2):186–193
   PubMed Web of Science ®Google Scholar
• . Nauck MA, Duran S, Kim D, . A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: A non-inferiority study. Diabetologia. 2007; 50(2):259–267
   PubMed Web of Science ®Google Scholar
• . Courrèges JP, Vilsboll T, Zdravkovic M, . Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabet Med. 2008; 25(9):1129–1131
   PubMed Web of Science ®Google Scholar
• . Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc; 2010
   Google Scholar
• . Victoza [package insert]. Princeton, NJ: Novo Nordisk Inc; 2010
   Google Scholar
• . Januvia [package insert]. Whitehouse Station, NJ: Merck and Co, Inc; 2010
   Google Scholar
• . Onglyza [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2009
   Google Scholar
• . Tradjenta [package insert]. Ridgefield, CT: Boehringer-Ingelheim Pharmaceuticals, Inc; 2011
   Google Scholar
• . Rodbard HW, Jellinger PS, Davidson JA, . Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: An algorithm for glycemic control. Endocr Pract. 2009; 15(6):540–559. https://www.aace.com/sites/default/fles/GlycemicControlAlgorithm.pdf. Published 2009. Accessed June 28, 2011
   PubMed Web of Science ®Google Scholar
• . Drucker DJ, Buse JB, Taylor K, ; DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study. Lancet. 2008; 372(9645):1240–1250
   PubMed Web of Science ®Google Scholar
• . Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993; 36(8):741–744
   PubMed Web of Science ®Google Scholar
• . Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993; 91(1):301–307
   PubMed Web of Science ®Google Scholar
• . Nauck MA, Ratner RE, Kapitza C, Berria R, Boldrin M, Balena R. Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: A double-blind placebo-controlled study. Diabetes Care. 2009; 32(7):1237–1243
   PubMed Web of Science ®Google Scholar
• . Deacon CF, Hughes TE, Holst JJ. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes. 1998; 47(5):764–769
   PubMed Web of Science ®Google Scholar
• . Vilsboll T, Zdravkovic M, Le Thi T, . Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007; 30(6):1608–1610
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R; CV181-011 Study Investigators. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr Med Res Opin. 2009; 25(10):2401–2411
   PubMed Web of Science ®Google Scholar
• . Kahn SE, Haffner SM, Heise MA, ; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355(23):2427–2443
   PubMed Web of Science ®Google Scholar
• . Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: A comparison of glyburide with other secret agogues and with insulin. Diabetes Care. 2007; 30(2):389–394
   PubMed Web of Science ®Google Scholar
• . Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev. 2001; 17(6):467–473
   PubMed Web of Science ®Google Scholar
• . Peyrot M, Rubin RR, Lauritzen T, . Resistance to insulin therapy among patients and providers: Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005; 28(11):2673–2679
   PubMed Web of Science ®Google Scholar
• . Blevins T, Pullman J, Malloy J, . DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011; 96(5):1301–1310
   PubMed Web of Science ®Google Scholar
• . Diamant M, Van GL, Stranks S, . Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): An open-label randomised trial. Lancet. 2010; 375(9733):2234–2243
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration. Saxagliptin. Adverse events of pancreatitis. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM149589.pdf. Published 2010. Accessed October 26, 2010
   Google Scholar
• . Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: A retrospective cohort study. Diabetes Care. 2009; 32(5):834–838
   PubMed Web of Science ®Google Scholar
• . Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: A retrospective observational pharmacy claims analysis. Diabetes Care. 2010; 33(11):2349–2354
   PubMed Web of Science ®Google Scholar
• . Dore DD, Seeger JD, Arnold CK. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin. 2009; 25(4):1019–1027
   PubMed Web of Science ®Google Scholar
• . Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide—the FDA's review of a new antidiabetic therapy. N Engl J Med. 2010; 362(9):774–777
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration. Byetta. NDA approval. Supplemental approval. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/021773s009s011s017s018s022s025021919ltr.pdf. Published 2009. Accessed January 12, 2010
   Google Scholar
• . US Food and Drug Administration. Victoza. NDA approval. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/022341s000ltr.pdf. Published 2010. Accessed July 15, 2010
   Google Scholar
• . US Food and Drug Administration. Januvia. Supplement approval. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/021995s010s011s012s014ltr.pdf. Published 2010. Accessed June 7, 2010
   Google Scholar
• . US Food and Drug Administration. Onglyza. NDA approval. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/022350s000ltr.pdf. Published 2009. Accessed July 15, 2010
   Google Scholar
• . US Food and Drug Administration. Tradjenta. NDA approval. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/201280s000ltr.pdf. Published 2011. Accessed May 23, 2011
   Google Scholar
• . Buse J, Montanya E, Sesti G, . Frequency and magnitude of antibody formation are lower with liraglutide than exenatide: LEAD-6 results. Paper presented at: American Diabetes Association 70th Scientific Sessions; June 25–29, 2010; Orlando, FL
   Google Scholar
• . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837–853
   PubMed Web of Science ®Google Scholar
• . Davidson JA, Brett J, Falahati A, Scott D. Mild renal impairment has no effect on the efficacy and safety of liraglutide. Endocr Pract. 2011; 17(3):345–355
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration. Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Published 2008. Accessed April 14, 2010
   Google Scholar
• . Bjerre KL, Madsen LW, Andersen S, . Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010; 151(4):1473–1486
   PubMed Web of Science ®Google Scholar
• . Hegedus L, Moses AC, Zdravkovic M, Le TT, Daniels GH. GLP-1 and calcitonin concentration in humans: Lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab. 2011; 96(3):853–860
   PubMed Web of Science ®Google Scholar
• . ClinicalTrials gov. Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results—A long term evaluation (LEADER). http://www.clinicaltrials.gov/ct2/show/NCT01179048?term=cardiovascular+AND+liraglutide&rank=1. Published 2010. Accessed February 9, 2011
   Google Scholar
• . Clinicaltrials.gov. Does saxagliptin reduce the risk of cardiovascular events when used alone or added to other diabetes medications (SAVOR-TIMI 53). http://www.clinicaltrials.gov/ct2/show/NCT01107886?term=cardiovascular+AND+saxagliptin&rank=1. Published 2011. Accessed February 9, 2011
   Google Scholar
• . Clinicaltrials.gov. CAROLINA: Cardiovascular outcomes study of linagliptin versus glimepiride in patients with type 2 diabetes. http://www.clinicaltrials.gov/ct2/show/NCT01243424?term=linagliptin&rank=13. Published 2011. Accessed September 21, 2011
   Google Scholar